Pakistan May Finalise Prices of 52 Life-Saving Drugs This Month

Pakistan is expected to move toward fixing the prices of 52 new life-saving medicines this month as the federal government prepares for a key meeting on drug pricing in Islamabad. The development involves Prime Minister Shehbaz Sharif, Federal Health Minister Syed Mustafa Kamal, Finance Minister Muhammad Aurangzeb and senior officials from the Drug Regulatory Authority of Pakistan.

According to the report, the meeting is scheduled for Monday and will focus on pending pricing matters linked to new medicines and hardship cases. Officials are expected to brief the prime minister on the status of approvals already completed by regulatory forums and the remaining steps required before formal notification.

The proposed pricing decision covers 52 medicines meant for serious and high-risk medical conditions. These include treatments linked to cancer, diabetes, hemophilia, autoimmune disorders and critical illnesses that require intensive care, making the matter significant for hospitals, patients and pharmaceutical suppliers across the country.

Sources cited in the report said the main purpose of the meeting is to secure the prime minister’s support for the pricing of the new medicines while also addressing unresolved hardship cases. The Cabinet’s Drug Pricing Committee and DRAP have already determined maximum retail prices for the new drugs, while the DRAP Policy Board and pricing committee have also given their approvals.

The issue is not limited to the new medicines alone. Around 100 hardship cases involving drugs used for different diseases are still awaiting final approval, according to the reported details. These cases usually involve pricing pressures where manufacturers seek adjustments because of production costs, supply conditions or market viability concerns.

Drug pricing remains one of Pakistan’s most sensitive health policy areas because it directly affects affordability for patients and the availability of essential treatments. When prices remain undecided for newly approved medicines, patients may face delays in access, while hospitals and pharmacies can struggle with supply planning.

For the government, the challenge is to balance public health needs with market realities. Lower prices can protect patients from unaffordable treatment costs, but delays or unsustainable rates may discourage companies from supplying certain specialized medicines, especially those used for rare, complex or life-threatening conditions.

The development also comes at a time when Pakistan’s healthcare system is under pressure from inflation, import costs and growing demand for specialized treatment. Families dealing with cancer, diabetes complications, blood disorders and intensive care needs often face heavy out-of-pocket expenses, making timely pricing decisions important for wider access.

Once Cabinet approval is granted, DRAP is expected to issue the official notification for the new drug prices. The next step will determine when the medicines enter the regulated market and whether the pending hardship cases are resolved in the same policy cycle.